Your Messages Inbox
Your Article Summary
See Latest ArticlesUCB to divest selected smaller markets to further focus on its key strategic areas 23-January-2009
UCB, 01/26/09
UCB has agreed with GlaxoSmithKline (GSK), to sell current UCB business and UCB affiliates in selected emerging markets for a cash compensation of EUR 515 million upon closing of the transaction expected in late March 2009. The commercial operations and product distribution rights to be acquired by GSK represent approximately 3-4% (three to four percent) of UCB's 2008 expected revenue of at least EUR 3.3 billion.
Today in Marketing/Media/ROI...keeping you current
Receive free subspecialty "5-minute updates" via email
Personalized Medicine Market To Grow 11% Annually
PharmExec, 12/16/09
Generic drugs dominate market, look to expand into biologics
Formulary , 12/16/09
Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09
Article Search
Sponsor